SCHEMBL367452

SCHEMBL367452

O=[As](O)(O)Oc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA4 P22748 2/20 0.46
CA9 Q16790 2/20 0.46
CA6 P23280 1/20 0.46
CA7 P43166 1/20 0.46
CA14 Q9ULX7 1/20 0.46
LTA4H P09960 2/20 0.41
TSHR P16473 1/20 0.41
SRC P12931 1/20 0.41
ALOX15 P16050 1/20 0.39
CA5A P35218 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
TDP1 Q9NUW8 3/20 0.38
NR1H2 P55055 1/20 0.37
BAX Q07812 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ALDH1A1 P00352 1/20 0.36
RECQL P46063 1/20 0.36
CA1 P00915 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2064518 0.84 CA4 (0.46) CA4CA9CA6CA7CA14
SCHEMBL10652895 0.81 TRPA1 (0.47) TSHRTDP1MAPTCYP2C19ALDH1A1
Dinitrophenylene SCHEMBL27976876 0.78 TSHR (0.55) TSHRALOX15MAPTALDH1A1
SCHEMBL15477270 0.78 CA4 (0.52) CA4CA9CA6CA7CA14
SCHEMBL2001538 0.78 CA4 (0.41) CA4CA9CA6CA7CA14
SCHEMBL28278624 0.78 CA4 (0.41) CA4CA9CA6CA7CA14
SCHEMBL712975 0.78 LTA4H (0.45) CA4CA9CA6CA7CA14
SCHEMBL22719969 0.77 MEN1 (0.48) CA4CA9CA14LTA4HALOX15
SCHEMBL27707183 0.77 CA9 (0.39) CA4CA9CA6CA7CA14
SCHEMBL10702292 0.75 TSHR (0.50) CA6CA14TSHRALOX15TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1000 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4640716-A2 METHODS FOR DETECTING RENAL DISEASE IDEXX Laboratories, Inc. (US) 2025-10-29 EP claimed
US-11739054-B2 Methods and compositions for substance use disorder vaccine formulations and uses thereof MOLECULAR EXPRESS, INC. (US) 2023-08-29 US claimed
US-11628216-B2 6-acetylmorphine analogs, and methods for their synthesis and use ALERE SAN DIEGO, INC. (US) 2023-04-18 US claimed
US-20220080042-A1 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE ALERE SAN DIEGO, INC. 2022-03-17 US claimed
EP-3458439-B1 2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE ALERE SAN DIEGO INC (US) 2021-12-08 EP claimed
US-11192857-B2 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use ALERE SAN DIEGO, INC. (US) 2021-12-07 US claimed
US-20210239704-A1 ANALOGS AND CONJUGATES OF BETA-AMINOISOBUTYRIC ACID (BAIB) IDEXX LABORATORIES, INC. 2021-08-05 US claimed
EP-3808733-A1 METHODS FOR DETECTING SYMMETRICAL DEMETHYLARGININE IDEXX Laboratories, Inc. (US) 2021-04-21 EP claimed
US-20210107862-A1 METHODS AND COMPOSITIONS FOR SUBSTANCE USE DISORDER VACCINE FORMULATIONS AND USES THEREOF MOLECULAR EXPRESS, INC. (US) 2021-04-15 US claimed
US-20200115324-A1 METHODS AND COMPOSITIONS FOR SUBSTANCE USE DISORDER VACCINE FORMULATIONS AND USES THEREOF MOLECULAR EXPRESS, INC. (US) 2020-04-16 US claimed
WO-2010017089-A1 METHODS FOR DETECTING SYMMETRICAL DEMETHYLARGININE IDEXX LABORATORIES, INC. (US) 2010-02-11 WO claimed
US-20090208451-A1 HALOGEN PHOSPHONATE MONOESTERS INTEGRIGEN, INC. (US) 2009-08-20 US claimed
US-20080293920-A1 Arginine Analogs, and Methods for Their Synthesis and Use ALERE SAN DIEGO, INC. (FKA BIOSITE INC. OR FKA CHOLESTECH CORP. OR FKA HEMOSENSE INC. OR FKA INVERNESS MEDICAL-BIOSTAR INC. OR FKA ISCHEMIA TECHNOLOGIES, INC. OR FKA TWISTDX, INC.) 2008-11-27 US claimed
WO-2006078813-A2 ARGININE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE BIOSITE INCORPORATED (US) 2006-07-27 WO claimed
WO-2005037228-A2 HALOGEN PHOSPHONATE MONOESTERS INTEGRIGEN, INC. (US) 2005-04-28 WO claimed
US-6605265-B1 Introducing hydrogen peroxide, ammonia and ketone or aldehyde into circulating reaction medium in azine reaction zone, withdrawing azine formed, heating medium, recycling to reaction zone, introducing reagent to maintain equilibrium ATOCHEM (FR) 2003-08-12 US claimed
EP-0796085-B1 SOLUBILISATION AIDS FOR HYDROPHILIC MACROMOLECULES PROVALIS UK LTD (GB) 2000-05-17 EP claimed
US-5968549-A Solubilisation aids CORTECS (UK) LIMITED (GB) 1999-10-19 US claimed
EP-0796085-A1 SOLUBILISATION AIDS FOR HYDROPHILIC MACROMOLECULES CORTECS LIMITED (GB) 1997-09-24 EP claimed
WO-1996017593-A1 SOLUBILISATION AIDS FOR HYDROPHILIC MACROMOLECULES CORTECS LIMITED (GB) 1996-06-13 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220080042-A1 6-ACETYLMORPHINE ANALOGS, AND METHODS FOR THEIR SYNTHESIS AND USE DNPEP, CRHBP, AANAT CA4 3445/4885CA9 3960/4885CA6 1147/4885
US-20200115324-A1 METHODS AND COMPOSITIONS FOR SUBSTANCE USE DISORDER VACCINE FORMULATIONS AND USES THEREOF TLR3, GAP43, MAG CA4 2794/4885CA9 3931/4885CA6 2622/4885
US-11628216-B2 6-acetylmorphine analogs, and methods for their synthesis and use DNPEP, CRHBP, AANAT CA4 3445/4885CA9 3960/4885CA6 1147/4885
US-20090208451-A1 HALOGEN PHOSPHONATE MONOESTERS FCGRT, PTMS, DNPEP CA4 113/4885CA9 288/4885CA6 335/4885
US-20080293920-A1 Arginine Analogs, and Methods for Their Synthesis and Use PRMT1, PRMT5, ARGLU1 CA4 3555/4885CA9 3952/4885CA6 3697/4885
US-20210107862-A1 METHODS AND COMPOSITIONS FOR SUBSTANCE USE DISORDER VACCINE FORMULATIONS AND USES THEREOF TLR3, GAP43, MAG CA4 2794/4885CA9 3931/4885CA6 2622/4885
US-11739054-B2 Methods and compositions for substance use disorder vaccine formulations and uses thereof TLR3, GAP43, MAG CA4 2794/4885CA9 3931/4885CA6 2622/4885
US-20210239704-A1 ANALOGS AND CONJUGATES OF BETA-AMINOISOBUTYRIC ACID (BAIB) GABRB1, GABRB2, GABRB3 CA4 1360/4885CA9 1079/4885CA6 1424/4885
US-11192857-B2 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use DPYSL2, DNPEP, DPYSL3 CA4 4230/4885CA9 4564/4885CA6 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.